Welcome to our dedicated page for Meiragtx Holdings Plc SEC filings (Ticker: MGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MeiraGTx Holdings plc filings document a clinical-stage genetic medicines company with ordinary shares listed on Nasdaq under MGTX. The company’s 8-K reports cover material definitive agreements, collaboration and license arrangements, asset purchases for genetic-medicine programs, Regulation FD clinical disclosures, operating and financial results, and amendments to note and warrant financing arrangements.
Its proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related corporate-governance disclosures. The filing record also documents capital structure, subsidiary guarantor arrangements, risk-oriented clinical and regulatory disclosures, and program-specific matters involving AAV-hAQP1, AAV-AIPL1, RPGR-related X-linked retinitis pigmentosa assets, and riboswitch technology.
MeiraGTx Holdings plc executive Richard Giroux reported a bona fide gift of company shares. The CFO & COO gifted 7,000 Ordinary Shares at a price of $0.0000 per share and now holds 964,530 Ordinary Shares directly. He also reports indirect ownership of 85,000 Ordinary Shares through Aigle Healthcare Partners III LLC and 5,152 Ordinary Shares held by his spouse.
MeiraGTx Holdings plc President & CEO Alexandria Forbes reported an open-market sale of 62,000 Ordinary Shares on May 19, 2026 at a weighted average price of $9.17 per share. The shares were sold in multiple trades between $8.96 and $9.32.
After this transaction, Forbes directly holds 1,387,695 Ordinary Shares. The sale was carried out under a Rule 10b5-1 trading plan that was adopted in advance, indicating the trades were pre-scheduled rather than opportunistic.
MGTX filed a Form 144 notice relating to proposed sales of 62,000 ordinary shares. The filing lists an Incentive Compensation Stock Grant dated 06/07/2018, records a sale dated 03/24/2026 of 62,000 shares, and includes numeric lines showing 459,420 and 568,540 alongside a 05/19/2026 entry.
MeiraGTx Holdings plc chief development officer Penny Renee Fleck reported compensation-related equity grants. She received 100,000 restricted share units, each convertible into one ordinary share upon vesting, and a stock option for 100,000 ordinary shares at an exercise price of $9.97 per share, vesting over several years with final option expiration on May 1, 2036.
MeiraGTx Holdings plc chief development officer Penny Renee Fleck reported compensation-related equity grants. She received 100,000 restricted share units, each convertible into one ordinary share upon vesting, and a stock option for 100,000 ordinary shares at an exercise price of $9.97 per share, vesting over several years with final option expiration on May 1, 2036.
MeiraGTx Holdings plc filed an initial insider ownership report for Penny Renee Fleck, who serves as Chief Development Officer. This Form 3 shows no reported transactions, derivative positions, or holdings, indicating a baseline disclosure of her status as a reporting officer without current share activity in this filing.
MeiraGTx Holdings plc filed an initial insider ownership report for Penny Renee Fleck, who serves as Chief Development Officer. This Form 3 shows no reported transactions, derivative positions, or holdings, indicating a baseline disclosure of her status as a reporting officer without current share activity in this filing.
MeiraGTx Holdings plc reported Q1 2026 results with service revenue of $293,000 and a net loss of $46.3 million, compared with $40.0 million a year earlier. Operating expenses were $41.1 million, driven mainly by research and development and manufacturing costs.
Cash, cash equivalents and restricted cash totaled $73.8 million at March 31, 2026, and management expects liquidity, including an additional $100.0 million public equity raise completed in Q2 2026 and a tax incentive receivable, to fund operations for at least twelve months, including a $25.0 million debt repayment due in June.
The company highlighted several strategic transactions: a new asset purchase agreement with Janssen to reacquire its RPGR retinal gene therapy program for an upfront $25.0 million plus contingent milestones and royalties; a collaboration with Lilly that brought an upfront $75.0 million and potential milestones of over $400.0 million; and a broad AI-enabled neurology collaboration with Hologen, featuring a committed $200.0 million upfront payment (of which $105.0 million had been received by March 31, 2026) and up to an additional $230.0 million in program funding.
MeiraGTx Holdings plc reported Q1 2026 results with service revenue of $293,000 and a net loss of $46.3 million, compared with $40.0 million a year earlier. Operating expenses were $41.1 million, driven mainly by research and development and manufacturing costs.
Cash, cash equivalents and restricted cash totaled $73.8 million at March 31, 2026, and management expects liquidity, including an additional $100.0 million public equity raise completed in Q2 2026 and a tax incentive receivable, to fund operations for at least twelve months, including a $25.0 million debt repayment due in June.
The company highlighted several strategic transactions: a new asset purchase agreement with Janssen to reacquire its RPGR retinal gene therapy program for an upfront $25.0 million plus contingent milestones and royalties; a collaboration with Lilly that brought an upfront $75.0 million and potential milestones of over $400.0 million; and a broad AI-enabled neurology collaboration with Hologen, featuring a committed $200.0 million upfront payment (of which $105.0 million had been received by March 31, 2026) and up to an additional $230.0 million in program funding.
MeiraGTx Holdings plc reported first quarter 2026 results and highlighted major regulatory, pipeline and financing milestones. Service revenue was $0.3 million for the quarter, while net loss widened to $46.3 million, or $0.57 per share. Cash, cash equivalents and restricted cash totaled $73.8 million as of March 31, 2026.
The company received FDA Breakthrough Therapy Designation for AAV2-hAQP1 in radiation-induced xerostomia and reported positive three-year Phase 1 data. It also entered an asset purchase agreement with Johnson & Johnson to reacquire botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa, which already has Fast Track, Orphan Drug and EU PRIME designations.
MeiraGTx strengthened its balance sheet with a $100 million public equity financing and expects, together with a $14.7 million tax incentive receivable and a remaining $95 million upfront payment from Hologen, to fund operations into the second half of 2028, while covering a $25 million upfront payment to J&J and scheduled debt repayments of $25 million in June 2026 and $50 million in July 2027.
MeiraGTx Holdings plc reported first quarter 2026 results and highlighted major regulatory, pipeline and financing milestones. Service revenue was $0.3 million for the quarter, while net loss widened to $46.3 million, or $0.57 per share. Cash, cash equivalents and restricted cash totaled $73.8 million as of March 31, 2026.
The company received FDA Breakthrough Therapy Designation for AAV2-hAQP1 in radiation-induced xerostomia and reported positive three-year Phase 1 data. It also entered an asset purchase agreement with Johnson & Johnson to reacquire botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa, which already has Fast Track, Orphan Drug and EU PRIME designations.
MeiraGTx strengthened its balance sheet with a $100 million public equity financing and expects, together with a $14.7 million tax incentive receivable and a remaining $95 million upfront payment from Hologen, to fund operations into the second half of 2028, while covering a $25 million upfront payment to J&J and scheduled debt repayments of $25 million in June 2026 and $50 million in July 2027.
MeiraGTx Holdings plc ownership disclosure: Adage Capital Management, L.P. and related reporting persons report 4,000,000 Ordinary Shares, representing 4.91% of the class. The percentage is calculated using 81,446,126 Ordinary Shares outstanding as of March 30, 2026, per the company's Form 10-K.
The filing (Amendment No. 6 to a Schedule 13G) attributes shared voting and shared dispositive power over the 4,000,000 shares to Adage and individuals Robert Atchinson and Phillip Gross. The business address for the reporting persons is noted as 200 Clarendon Street, Boston, Massachusetts.
MeiraGTx Holdings plc is asking shareholders to elect three Class II directors and ratify Ernst & Young LLP as independent auditor at its 2026 virtual annual meeting. The meeting will be held on June 11, 2026 at 10:00 a.m. Eastern Time via webcast.
Shareholders of record as of April 21, 2026, holding 92,573,523 ordinary shares, may attend and vote, with a quorum reached when at least one third of voting share capital is represented. The board recommends voting for all director nominees and for auditor ratification.
The proxy also outlines corporate governance practices, committee structures and 2025 executive pay. In 2025, CEO Alexandria Forbes received total compensation of $8.33 million, including an $840,000 salary, $1.65 million bonus and equity awards. CFO/COO Richard Giroux received $8.15 million, and CMO Robert Zeldin received $1.62 million.